In vitro and in vivo antitumor properties of tetrakis((trishydroxymethyl)phosphine)gold(I) chloride

Journal of Medicinal Chemistry

Volumn 46, Issue 7, 2003, Pages 1130-1132

  Pillarsetty, Nagavarakishore ^a,b   Katti, Kavita K ^b   Hoffman, Timothy J ^b   Volkert, Wynn A ^b,c   Katti, Kattesh V ^a,b   Kamei, Hideo ^d   Koide, Tatsurou ^d  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GOLD DERIVATIVE; TETRAKIS[(TRISHYDROXYMETHYL)PHOSPHINE]GOLD CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; COLON CARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; FLOW CYTOMETRY; GASTROINTESTINAL TUMOR; HUMAN; HUMAN CELL; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PROSTATE TUMOR; SARCOMA; SURVIVAL TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; ORGANOGOLD COMPOUNDS; ORGANOMETALLIC COMPOUNDS; PHOSPHINES; TUMOR CELLS, CULTURED;

EID: 0037468817     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm025615g     Document Type: Article

References (25)

1. Berglof, F. E.; Berglof, K.; Walz, D. T. Auranofin: an oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. J. Rheumatol. 1978, 5, 68-74.
2. Bendix, G.; Bjelle, A. A 10-year follow-up of parenteral gold therapy in patients with rheumatoid arthritis. Ann. Rheum. Dis. 1996, 55, 169-176.
3. Shaw, C. F., III. Gold based therapeutic agents. Chem. Rev. 1999, 99, 2589-2600.
4. Shaw, C. F., III.; Beery, A.; Stocco, G. C. Antitumor activity of two binuclear gold (I) complexes with bridging dithiolate ligands. Inorg. Chim. Acta 1986, 123, 213-216.
5. Koide, T.; Kojima, T.; Kamei, H. Antitumor effect of gold as revealed by growth suppression of cultured cancer cells. Cancer Biother. Radiopharm. 1998, 13, 189-192.
6. Sadler, P. J.; Sue, R. E. The chemistry of gold drugs. Met.-Based Drugs 1994, 1, 107-144.
7. Mirabelli, C. K.; Hill, D. T.; Faucette, L. F.; McCabe, F. L.; Girard, G. R.; Bryan, D. B.; Sutton, B. M.; Bartus, J.; Crooke, S. T.; Johnson, R. K. Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds. J. Med. Chem. 1987, 30, 2181-2190.
8. Mirabelli, C. K.; Johnson, R. K.; Sung, C. M.; Faucette, L.; Muirhead, K.; Crooke, S. T. Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. Cancer Res. 1985, 45, 32-39.
9. Buckley, R. G.; Elsome, A. M.; Fricker, S. P.; Henderson, G. R.; Theobald, B. R. C.; Parish, R. V.; Howe, B. P.; Kelland, L. R. Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes. J. Med. Chem. 1996, 39, 5208-5214.
10. Carotti, S.; Guerri, A.; Mazzei, T.; Messori, L.; Mini, E.; Orioli, P. Gold(III) compounds as potential antitumor agents: cytotoxicity and DNA binding properties of some selected polyamine-gold(III) complexes. Inorg. Chim. Acta 1998, 281, 90-94.
11. Messori, L.; Abbate, F.; Marcon, G.; Orioli, P.; Fontani, M.; Mini, E.; Mazzei, T.; Carotti, S.; O'Connell, T.; Zanello, P. Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds. J. Med. Chem. 2000, 43, 3541-3548.
12. Messori, L.; Marcon, G.; Tempi, C.; Orioli, P. Interactions of selected gold(III) complexes with calf thymus DNA. Biochem. Biophys. Res. Commun. 2001, 281, 352-360.
13. Coronnello, M.; Marcon, G.; Carotti, S.; Caciagli, B.; Mazzei, T.; Mini, E.; Orioli, P.; Messori, L. Cytotoxicity, DNA damage and cell cycle perturbations induced by two representative gold(III) complexes in human leukemic cells with different cisplatin sensivity. Oncol. Res. 2001, 12, 361-370.
14. Marcon, G.; Carotti, S.; Coronnello, M.; Messori, L.; Mini, E.; Orioli, P.; Mazzei, T.; Cinellu, M. A.; Minghetti, G. Gold(III) Complexes with Bipyridyl Ligands: Solution Chemistry, Cytotoxicity, and DNA Binding Properties. J. Med. Chem. 2002, 45, 1672-1677.
15. Hoke, G. D.; Macia, R. A.; Meunier, P. C.; Bugelski, P. J.; Mirabelli, C. K.; Rush, G. F.; Matthews, W. D. In vivo and in vitro cardiotoxicity of a gold containing antineoplastic drug candidate in the rabbit. Toxicol. Appl. Pharmacol. 1989, 100, 293-306.
16. McKeage, M. J.; Maharaj, L.; Berners-Price, S. J. Mechanism of cytotoxicity and antitumor activity of gold(I) phosphine complexes: the possible role of mitochondria. Coord. Chem. Rev. 2002, 232, 127-135.
17. Katti, K. V.; Gali, H.; Berning, D. E.; Smith, C. J. Design and development of functionalized water-soluble phosphines: Catalytic and biomedical implications. Acc. Chem. Res. 1999, 32, 9-17.
18. + gold(I) complexes. Chem. Ber. 1997, 130, 907-911.
19. 188Re of peptide conjugates containing a dithiabisphosphine chelating agent. Bioconjugate Chem. 2001, 12, 354-363.
20. Raghuraman, K.; Pillarsetty, N.; Volkert, W. A.; Barnes, C.; Jurisson, S.; Katti, K. V. Exceptional kinetic propensity of hydroxymethyl phosphanes toward Rh(III) stabilization in water. J. Am. Chem. Soc. 2002, 124, 7276-7277.
21. Sandhu, C.; Slingerland, J. Deregulation of the cell cycle in cancer. Cancer Detect. Prev. 2000, 24, 107-118.
22. Sherr, C. J. The pezcoller lecture: Cancer cell cycles revisited. Can. Res. 2000, 60, 3689-3695.
23. Webster, K. R. Therapeutic potential of targeting the cell cycle. Chem. Res. Toxicol. 2000, 13, 940-943.
24. + induced by thiols and blood plasma. Inorg. Chem. 1987, 26, 3074-3077.
25. Berners-Price, S. J.; Sadler, P. J. Coordination chemistry of metallodrugs: insights into biological speciation from NMR spectroscopy. Coord. Chem. Rev. 1996, 151, 1-40.